Xeloda Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Conditions:   Tislelizumab;   Bevacizumab;   Oxaliplatin;   Capecitabine;   MSS/pMMR;   Metastatic Colorectal Cancer (mCRC);   RAS-mutated;   First-Line Intervention:   Drug: Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine Sponsor:   Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials